Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurotrauma ; 30(12): 1023-34, 2013 Jun 15.
Article in English | MEDLINE | ID: mdl-23557244

ABSTRACT

Blocking the action of inhibitory molecules at sites of central nervous system injury has been proposed as a strategy to promote axonal regeneration and functional recovery. We have previously shown that genetic deletion or competitive antagonism of EphA4 receptor activity promotes axonal regeneration and functional recovery in a mouse model of lateral hemisection spinal cord injury. Here we have assessed the effect of blocking EphA4 activation using the competitive antagonist EphA4-Fc in a rat model of thoracic contusive spinal cord injury. Using a ledged tapered balance beam and open-field testing, we observed significant improvements in recovery of locomotor function after EphA4-Fc treatment. Consistent with functional improvement, using high-resolution ex vivo magnetic resonance imaging at 16.4T, we found that rats treated with EphA4-Fc had a significantly increased cross-sectional area of the dorsal funiculus caudal to the injury epicenter compared with controls. Our findings indicate that EphA4-Fc promotes functional recovery following contusive spinal cord injury and provides further support for the therapeutic benefit of treatment with the competitive antagonist in acute cases of spinal cord injury.


Subject(s)
Immunoglobulin Fc Fragments/pharmacology , Receptor, EphA4/antagonists & inhibitors , Recovery of Function/drug effects , Spinal Cord Injuries/drug therapy , Animals , Blotting, Western , Brain/drug effects , Brain/pathology , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Female , Humans , Magnetic Resonance Imaging , Rats , Rats, Wistar , Recombinant Fusion Proteins/pharmacology , Spinal Cord Injuries/pathology , Transfection
2.
PLoS One ; 6(9): e24636, 2011.
Article in English | MEDLINE | ID: mdl-21931787

ABSTRACT

Upregulation and activation of developmental axon guidance molecules, such as semaphorins and members of the Eph receptor tyrosine kinase family and their ligands, the ephrins, play a role in the inhibition of axonal regeneration following injury to the central nervous system. Previously we have demonstrated in a knockout model that axonal regeneration following spinal cord injury is promoted in the absence of the axon guidance protein EphA4. Antagonism of EphA4 was therefore proposed as a potential therapy to promote recovery from spinal cord injury. To further assess this potential, two soluble recombinant blockers of EphA4, unclustered ephrin-A5-Fc and EphA4-Fc, were examined for their ability to promote axonal regeneration and to improve functional outcome following spinal cord hemisection in wildtype mice. A 2-week administration of either of these blockers following spinal cord injury was sufficient to promote substantial axonal regeneration and functional recovery by 5 weeks following injury. Both inhibitors produced a moderate reduction in astrocytic gliosis, indicating that much of the effect of the blockers may be due to promotion of axon growth. These studies provide definitive evidence that soluble inhibitors of EphA4 function offer considerable therapeutic potential for the treatment of spinal cord injury and may have broader potential for the treatment of other central nervous system injuries.


Subject(s)
Axons/physiology , Nerve Regeneration/drug effects , Receptor, EphA4/metabolism , Recombinant Proteins/therapeutic use , Recovery of Function/drug effects , Spinal Cord Injuries/drug therapy , Animals , Axons/drug effects , Axons/metabolism , Immunoglobulin Fc Fragments/genetics , Immunoglobulin Fc Fragments/metabolism , Immunohistochemistry , Mice , Mice, Inbred C57BL , Receptor, EphA4/antagonists & inhibitors , Recombinant Proteins/genetics , Recombinant Proteins/metabolism
3.
J Neurol Sci ; 252(1): 9-12, 2007 Jan 15.
Article in English | MEDLINE | ID: mdl-17109894

ABSTRACT

UNLABELLED: Multiple Sclerosis (MS) is a central nervous system (CNS) chronic inflammatory demyelinating disease leading to various neurological disabilities. The disorder is more prevalent for women with a ratio of 3:2 female to male. OBJECTIVES: To investigate variation within the estrogen receptor 1 (ESR1) polymorphism gene in an Australian MS case-control population using two intragenic restriction fragment length polymorphisms; the G594A located in exon 8 detected with the BtgI restriction enzyme and T938C located in intron 1, detected with PvuII. One hundred and ten Australian MS patients were studied, with patients classified clinically as Relapsing Remitting MS (RR-MS), Secondary Progressive MS (SP-MS) or Primary Progressive MS (PP-MS). Also, 110 age, sex and ethnicity matched controls were investigated as a comparative group. No significant difference in the allelic distribution frequency was found between the case and control groups for the ESR1 PvuII (P = 0.50) and Btg1 (P = 0.45) marker. Our results do not support a role for these two ESR1 markers in multiple sclerosis susceptibility, however other markers within ESR1 should not be excluded for potential involvement in the disorder.


Subject(s)
Estrogen Receptor alpha/genetics , Multiple Sclerosis/genetics , Polymorphism, Genetic , Alleles , Australia/epidemiology , Case-Control Studies , Chi-Square Distribution , DNA Mutational Analysis , Exons , Female , Gene Frequency , Humans , Introns , Linkage Disequilibrium , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...